H. Alexander, J. Harpprecht, H. -. Podzuweit, P. Rautenberg, W. Müller‐ruchholtz
{"title":"Human monoclonal antibodies recognize early and late viral proteins of human cytomegalovirus.","authors":"H. Alexander, J. Harpprecht, H. -. Podzuweit, P. Rautenberg, W. Müller‐ruchholtz","doi":"10.3233/HAB-1994-51-211","DOIUrl":"https://doi.org/10.3233/HAB-1994-51-211","url":null,"abstract":"Human monoclonal antibodies directed against human cytomegalovirus were generated by fusion of in vitro stimulated human spleen lymphocytes from an HCMV-seropositive 53-year-old organ donor with the mouse myeloma cell line Ag8.653. Fourteen human/mouse hybridomas producing anti-cytomegalovirus IgG were screened by an ELISA technique and four selected clones have been established since March 1988, generating about 5-40 micrograms/24 h IgG per ml culture supernatant. Reference and local cytomegalovirus strains were stained by the antibodies without showing cross-reactivity to other herpes viruses. Three monoclonal antibodies, A4B4 (IgG11), A6B3 (IgG1k) and A6A2 (IgG1k), immunoprecipitated a 68 kDa early viral protein which appears during the infectious cycle, first in the nucleus (18-24 h) and then also in the cytoplasm (24-96 h) of infected cells. Inhibition of DNA replication restricted the detection of the 68 kDa viral protein to the nucleus of infected cells. Staining of unfixed infected cells showed that two of the antibodies bound at the surface of a few cells. The fourth monoclonal antibody A3C5 (IgG11) immunoprecipitated a 34/38 kDa late viral protein which appears in the nucleus (48-72 h) of infected cells. These antibodies enable us to study the human host response to human cytomegalovirus and to elucidate the functions of human antibodies especially in their interaction with the T-cell response.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2 1","pages":"81-90"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1994-51-211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69905979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Major, R. Liou, L. Sun, L. Yu, S. Starnes, M. Fung, T. Chang, N. Chang
{"title":"Construction and characterization of chimeric and humanized forms of a broadly neutralizing monoclonal antibody to HIV-1.","authors":"J. Major, R. Liou, L. Sun, L. Yu, S. Starnes, M. Fung, T. Chang, N. Chang","doi":"10.3233/HAB-1994-51-202","DOIUrl":"https://doi.org/10.3233/HAB-1994-51-202","url":null,"abstract":"Murine monoclonal antibody (MAb) G3-519 has been shown to recognize a conserved neutralizing epitope in the fourth constant (C4) region of the external glycoprotein gp120 of HIV-1. Inasmuch as this antibody effectively neutralized the infectivity of diverse HIV-1 isolates, it has been selected to be developed for passive immunization against HIV-1 infection in humans. In order to minimize the problem of immunogenicity of murine antibodies and to confer additional accessory immune functions, we have constructed mouse/human chimeric and humanized forms of the antibody. The chimeric antibody was constructed by cloning the murine variable regions and replacing the mouse constant regions with those from human Ig gamma 1,kappa. The humanized antibody was constructed using the human KAS variable region framework sequences as template. Engineering was guided by a three dimensional model of the murine variable region. The murine, chimeric and humanized forms of the antibody exhibited similar reactivity with the peptidic antigen in ELISA, and comparably neutralized the infectivity of HIV-1 in vitro. Taken together, our results show that the chimeric and humanized forms of G3-519 essentially retain the binding activity of the mouse parental antibody. Clinical development is planned to assess the prophylactic and therapeutic usefulness of these reshaped antibodies in humans.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2 1","pages":"9-17"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1994-51-202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69906234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Design and analysis of PCR primers for the amplification and cloning of human immunoglobulin Fab fragments.","authors":"M de Boer, S Y Chang, G Eichinger, H C Wong","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have developed PCR primers for the amplification and cloning of the genes encoding human antibody fragments. Two sets of primers were designed to amplify the coding sequence of the complete variable region and the first constant domain of immunoglobulin heavy chains. One set of primers was designed to amplify the coding sequence of complete kappa light chains. These three sets of primers were used in PCR amplifications with cDNA prepared from EBV transformed B cells as the template. The amplified fragments were cloned and their nucleotide sequences were determined. Analysis of the DNA sequences of such PCR generated antibody fragments suggested that our primer sets were able to amplify the major subsets of the heavy and light chain variable region genes. Comparison between the estimated frequency of the different subsets of heavy chain variable region genes and the distribution of our subclones further indicated that one set of our primers was able to proportionally amplify the subsets of the heavy chain family.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2","pages":"57-64"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18855966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human monoclonal Fab fragments from a combinatorial library prepared from an individual with a low serum titer to a virus.","authors":"E Bender, G R Pilkington, D R Burton","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An IgG1k lambda Fab library was generated on the surface of phage beginning with bone marrow RNA from a healthy 22-year-old human donor. The donor had been immunized to measles in his early childhood but had only a low serum titer to a measles antigen preparation. The resulting library of approximately 10(7) clones was panned against the measles antigen preparation and three positive Fab-producing clones identified by ELISA. One of the Fabs was found to be specific to measles and to bind with high apparent affinity (10(8) M-1). The other two bind with lower affinity and show marked cross-reactivity with a number of other antigens. They possess heavy chains derived, with extensive somatic modification, from the single member gene family VH6. The study indicates that both high-affinity specific antibodies and lower affinity polyreactive antibodies can be derived from the library approach under appropriate conditions.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18855962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T C Peakman, J Worden, R H Harris, H Cooper, J Tite, M J Page, D R Gewert, M Bartholemew, J S Crowe, S Brett
{"title":"Comparison of expression of a humanized monoclonal antibody in mouse NSO myeloma cells and Chinese hamster ovary cells.","authors":"T C Peakman, J Worden, R H Harris, H Cooper, J Tite, M J Page, D R Gewert, M Bartholemew, J S Crowe, S Brett","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report a detailed comparison of two commonly used stable, amplifiable mammalian expression systems (Chinese Hamster Ovary cells/dihydrofolate reductase and Mouse NSO myeloma/glutamine synthetase) used to express a humanized IgG1 monoclonal antibody. We compare copy number and steady state mRNA levels of both the selectable marker and heavy chain of the antibody throughout the selection and amplification process. In both cell lines, copy number and steady state levels of heavy chain and selectable marker increased during selection and were further increased during amplification. As expected, an increase in steady state mRNA levels of heavy chain correlated with an increase in expression of antibody whilst an increase in the steady state levels of mRNA of the selectable marker correlated with increased resistance to the selective agent. In NSO and CHO cells producing equivalent amounts of antibody, the copy number of the antibody genes and selectable marker was significantly higher in the CHO cells than in the NSO cells. However, the steady state mRNA levels of the heavy chain of the antibody were virtually identical. Rates of protein secretion in the two cell lines were also compared and found to be very similar. When the antibody purified from both systems was compared in a number of functional assays they behaved identically.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18539622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anti-glycolipid antibodies produced by Epstein-Barr virus (EBV)-transformed oligoclonal B cell lines obtained from normal persons and autoimmune disease patients.","authors":"Y Nagatsuka, S Hanazawa, T Yasuda, Y Ono","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Oligoclonal B-lymphoblastoid cell lines (LCL) were blindly established by nonimmunized protocol from natural populations of two normal persons and 8 autoimmune disease patients using Epstein-Barr virus (EBV)-induced transformation. We systematically screened these LCLs on antibodies against a panel of glycolipids using liposome immune lysis assay (LILA). Eventually we found antibodies to 12 out of 15 compounds containing CTH, globoside, Forssman, paragloboside, CPH, sulfatide, NAGM3, NGGM3, i active glycolipid, GM1, GA1 and GA2 in 81 out of 950 LCLs from normal PBL, and antibodies to 2 out of 15 compounds containing sulfatide and CPH were also detected in 11 out of 430 LCLs from autoimmune disease patients. Unexpectedly, the antibody repertoire of LCLs from autoimmune disease patients was impoverished. The possibility of the EBV technique for production of various kinds of human monoclonal antibodies (MAbs) to glycolipid was shown.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 3-4","pages":"183-6"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18759967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M Shoji, S Kawamoto, S Sato, M Kamei, M Kato, S Hashizume, K Seki, K Yasumoto, A Nagashima, H Nakahashi
{"title":"Specific reactivity of human monoclonal antibody AE6F4 against cancer cells in tissues and sputa from lung cancer patients.","authors":"M Shoji, S Kawamoto, S Sato, M Kamei, M Kato, S Hashizume, K Seki, K Yasumoto, A Nagashima, H Nakahashi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In vitro immunization of normal human peripheral lymphocytes by the co-cultivation with A549 cells (a human lung adenocarcinoma cell line), followed by the hybridization with the partner cell line A4H12, resulted in the efficient generation of hybridomas which produce human monoclonal antibodies of IgG or IgM isotype. Immunohistochemical and immunocytological studies showed that one of those monoclonal antibodies, termed AE6F4, was specifically reactive to lung cancer tissues as well as cancer cells in sputa.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 3-4","pages":"116-22"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18757275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Heveker, A. Hansen, K. Hungerer, R. von Baehr, R. Glaser
{"title":"A human monoclonal antibody with the capacity to neutralize Staphylococcus aureus alpha-toxin.","authors":"N. Heveker, A. Hansen, K. Hungerer, R. von Baehr, R. Glaser","doi":"10.3233/HAB-1994-51-203","DOIUrl":"https://doi.org/10.3233/HAB-1994-51-203","url":null,"abstract":"A human monoclonal antibody, CB STL-1, against staphylococcal alpha-toxin has been established by hybridoma technology. It is of IgG1 subclass with lambda light chain and possesses a dissociation constant of 8 x 10(-10) mol/l. 1 mg of purified antibody neutralizes the hemolytic activity of 800 micrograms/ml alpha-toxin in an in vitro hemolysis assay using rabbit erythrocytes. The antibody does not bind to overlapping (7 residues) decapeptides spanning the sequence of alpha toxin, thus it might bind to a conformational epitope. The epitope recognized by the antibody is not accessible in oligomeric toxin. The antibody binds both to the hydrophilic and amphipathic forms of the monomeric toxin Fab fragments of the antibody are stable and show no significant loss of activity. CB STL-1 was able to protect mice in vivo from i.p. challenge with alpha toxin. Thus, the antibody is a candidate for passive immunotherapy. The variable regions of the antibody secreted by CB STL-1 were sequenced and found to be encoded by a VH gene segment belonging to the VH1 family, and a Vlambda segment most likely belonging to the VlambdaIII subgroup. Further analysis concerning the third complementarity determining region (CDR3) of the heavy chain is presented.","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2 1","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-1994-51-203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69906243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Anti-Tn human monoclonal antibodies generated following active immunization with partially desialylated ovine submaxillary mucin.","authors":"K P O'Boyle, K Wright","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Partially desialylated ovine submaxillary mucin plus an immunological adjuvant has been used by us to induce a humoral immune response to Tn antigen and sialylated Tn in colon cancer patients at risk of recurrence. Peripheral blood lymphocytes were purified from one of these patients with a high IgM titer reactive with Tn antigen transformed with Epstein-Barr virus and subsequently fused with a human-mouse heteromyeloma cell line, HMMA2.11TG/O. Clones were screened and subcloned using an enzyme-linked immunoassay and four stable IgM-secreting clones were tested for reactivity with a variety of natural and synthetic antigens, paraffin-embedded colon carcinomas and normal colonic mucosa to determine their specificity. Four human IgM monoclonal antibodies reactive predominantly with Tn antigen were produced and shown to react with a mucinous human colon carcinoma cell line, LS-174T, and with paraffin-embedded human colon carcinomas. We conclude that modified ovine submaxillary mucin is an effective vaccine for generating a humoral immune response directed to Tn antigen present on human colon cancer.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 1-2","pages":"25-31"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18539621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the Gal alpha 1-3 Gal epitope.","authors":"R F Montaño, E L Romano","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The presence of the Gal alpha 1-3 Gal structure (Gal epitope) in the carbohydrate component of fifteen human monoclonal antibodies with specificity for the Rh blood group factor and produced by human-mouse heterohybridomas was evaluated. To do that, an antiglobulin-like agglutination test and an enzyme linked immunosorbent assay were performed using an affinity-purified anti-Gal antibody obtained from the serum of an AB blood group donor. Using the antiglobulin reaction, results were obtained showing that only five of the fifteen human monoclonal antibodies tested contained the structure at levels sufficient to allow agglutination. However, all fifteen monoclonals were positive using the more sensitive enzyme linked immunosorbent assay. By means of an indirect immunofluorescence assay the same anti-Gal antibody was used to test the presence of Gal epitopes on the surface of the producer heterohybridomas. Results were obtained indicating that twelve out of the fifteen hybridomas studied do express the Gal structure on its surface. The relevance of these findings is discussed in the context of therapeutic applications of human monoclonal antibodies.</p>","PeriodicalId":77166,"journal":{"name":"Human antibodies and hybridomas","volume":"5 3-4","pages":"152-6"},"PeriodicalIF":0.0,"publicationDate":"1994-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18546690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}